📣 VC round data is live. Check it out!
- Public Comps
- Brightgene Bio-medical
Brightgene Bio-medical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Brightgene Bio-medical and similar public comparables like Virbac, Organon, Edgewise Therapeutics, Laboratorios Rovi and more.
Brightgene Bio-medical Overview
About Brightgene Bio-medical
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
Founded
2001
HQ

Employees
N/A
Website
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialBrightgene Bio-medical Financials
Brightgene Bio-medical reported last 12-month revenue of $182M and EBITDA of $52M.
In the same LTM period, Brightgene Bio-medical generated $92M in gross profit, $52M in EBITDA, and $10M in net income.
Revenue (LTM)
Brightgene Bio-medical P&L
In the most recent fiscal year, Brightgene Bio-medical reported revenue of $180M and EBITDA of $36M.
Brightgene Bio-medical is profitable as of last fiscal year, with gross margin of 51%, EBITDA margin of 20%, and net margin of 4%.
Financial data powered by Morningstar, Inc.
Brightgene Bio-medical Stock Performance
Brightgene Bio-medical has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Brightgene Bio-medical's stock price is $8.12.
Brightgene Bio-medical share price decreased by 12.0% in the last 30 days, and increased by 8.2% in the last year.
Brightgene Bio-medical has an EPS (earnings per share) of $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -3.6% | -12.0% | 20.8% | 8.2% | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBrightgene Bio-medical Valuation Multiples
Brightgene Bio-medical trades at 20.8x EV/Revenue multiple, and 73.3x EV/EBITDA.
EV / Revenue (LTM)
Brightgene Bio-medical Financial Valuation Multiples
As of May 27, 2026, Brightgene Bio-medical has market cap of $4B and EV of $4B.
Brightgene Bio-medical has a P/E ratio of 347.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Brightgene Bio-medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Brightgene Bio-medical Margins & Growth Rates
Brightgene Bio-medical grew revenue by 5% and EBITDA by 104% in the last fiscal year.
In the most recent fiscal year, Brightgene Bio-medical reported gross margin of 51%, EBITDA margin of 20%, and net margin of 4%.
Brightgene Bio-medical Margins
Brightgene Bio-medical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Brightgene Bio-medical Operational KPIs
Brightgene Bio-medical's Rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Brightgene Bio-medical's Rule of X is 52% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Brightgene Bio-medical Competitors
Brightgene Bio-medical competitors include Virbac, Organon, Edgewise Therapeutics, Laboratorios Rovi, Erasca, Zealand Pharma, Viking Therapeutics, Zhejiang Huahai, ACADIA Pharmaceuticals and Genscript Biotech.
Most Brightgene Bio-medical public comparables operate across Biopharmaceuticals, Contract Research & Manufacturing, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.2x | 2.2x | 11.2x | 10.8x | |||
| 1.8x | 1.8x | 5.8x | 5.8x | |||
| - | - | (16.0x) | (14.8x) | |||
| 4.0x | 4.1x | 14.9x | 13.9x | |||
| - | - | (25.7x) | (15.7x) | |||
| 0.9x | 1.1x | 1.2x | 1.8x | |||
| - | - | (7.6x) | (6.1x) | |||
| 3.5x | 3.5x | 18.0x | 16.9x | |||
This data is available for Pro users. Sign up to see all Brightgene Bio-medical competitors and their valuation data. Start Free Trial | ||||||
Brightgene Bio-medical Funding History
Before going public, Brightgene Bio-medical raised $81M in total equity funding, across 1 round.
Brightgene Bio-medical Funding Rounds
Brightgene Bio-medical Investment Activity
Brightgene Bio-medical has invested in 2 companies to date.
Latest investment by Brightgene Bio-medical was on July 2nd 2020. Brightgene Bio-medical invested in Citryll in their $22M Series B round (EV/Revenue multiple of ).
Latest Investments by Brightgene Bio-medical
| Description | Citryll is a biopharmaceutical company developing PAD4 inhibitors targeting NETosis for autoimmune diseases including lupus, vasculitis, rheumatoid arthritis, pulmonary fibrosis, and sepsis-related organ damage. Oss-headquartered in the Netherlands since 2015, the firm advances small-molecule drugs that block peptidylarginine deiminase enzymes to reduce inflammation and tissue injury. | DNALite Therapeutics is a preclinical biotechnology company developing oral lipid nanoparticles for mRNA and plasmid DNA delivery to the gastrointestinal tract. Based in Israel, the firm engineers intestine-specific secretion of therapeutic proteins into the bloodstream, converting injectables like insulin into pills. Founded in 2019, DNALite targets inflammatory bowel disease and metabolic disorders, with lead candidates demonstrating oral bioavailability in animal models. |
| HQ Country | ||
| HQ City | Oss | San Francisco, CA |
| Deal Date | 2 Jul 2020 | 8 Aug 2018 |
| Round | Series B | Seed |
| Raised | $22M | $2M |
| Investors | BioGeneration Ventures; BOM; Brightgene Bio-medical; ModiQuest B.V.; Seventure Partners | Berkeley Catalyst Fund (BCF); Blue Bear Ventures; Brightgene Bio-medical; SOSV; SVE Capital; University of California Berkeley |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Brightgene Bio-medical investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Brightgene Bio-medical
| Who are competitors of Brightgene Bio-medical? | Brightgene Bio-medical main competitors include Virbac, Organon, Edgewise Therapeutics, Laboratorios Rovi, Erasca, Zealand Pharma, Viking Therapeutics, Zhejiang Huahai, ACADIA Pharmaceuticals, Genscript Biotech. |
See public comps similar to Brightgene Bio-medical
Lists including Brightgene Bio-medical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

